Valo Therapeutics has secured €19 million in funding to expand its clinical trials for a new cancer immunotherapy, PeptiCRAd, enhancing its operations in Italy.

Target Information

Valo Therapeutics Oy, a Finnish company co-founded by Professor Vincenzo Cerullo from Naples, is at the forefront of developing an innovative immunotherapy for cancer. The company is primarily focusing on its leading therapeutic candidate, PeptiCRAd, which utilizes oncolytic viruses coated with tumor antigens to enhance the immune response in patients with solid tumors. This funding round will enable Valo to expand its Phase 1B clinical trial for PeptiCRAd across Italy, Australia, and Germany.

The capital raised will also support the establishment of Valo Therapeutics Italy Srl in Naples, aiming to bolster strategic initiatives in Southern Italy. The focus will be on patient recruitment and treatment, large-scale production of oncolytic viruses, and research collaborations with local academic and scientific institutions.

Industry Overview in Italy

The biotechnology industry in Italy has been experiencing significant growth, bolstered by both government support and private investments aimed at fostering innovation. The country b